VGX-1027
VGX-1027 displays immunomodulatory and anti-inflammatory activities by inhibiting toll-like receptor 4 (TLR4) signaling. In diabetic mice, VGX-1027 decreases synthesis of pro-inflammatory cytokines and improves glomerulosclerosis. In other animal models, this compound inhibits antigen presentation, preventing the development of systemic lupus erythmatosus (SLE), increases survival rates and improving overall pathology.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18978796
| Cas No. |
6501-72-0 |
|---|---|
| Formula |
C11H11NO3 |
| Formula Wt. |
205.21 |
| IUPAC Name |
(3-Phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid |
| Synonym |
GIT27 |
Fagone P, Muthumani K, Mangano K, et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology. 2014 Aug;142(4):594-602. PMID: 24527796.
Cha JJ, Hyun YY, Lee MH, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology. 2013 Jun;154(6):2144-55. PMID: 23568555.
Stojanovic I, Cuzzocrea S, Mangano K, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immunol. 2007 Jun;123(3):311-23. PMID: 17449326.
